Merck Serono makes first awards for multiple sclerosis innovation

09-Oct-2013 - Germany

Merck Serono announced on the occasion of the 29th European Committee for Treatment and Research in multiple sclerosis (ECTRIMS), the recipients of the company’s inaugural Grant for Multiple Sclerosis Innovation (GMSI).

Four recipients, three from the United States and one from Germany, will share the overall €1 million grant to support their research:

Dr. Daniel Harrison, Assistant Professor of Neurology at the Johns Hopkins University School of Medicine, received a grant for research seeking to translate novel magnetic resonance imaging and analysis techniques into tools that have clinical applications in MS. He is focused on the validation of tools that will provide more pathologically specific assessments in future clinical trials.

Dr. Thomas Thum, Professor and Director of the Institute of Molecular and Translational Therapeutic Strategies at Hannover Medical School (Germany), previously evaluated whether microRNAs are differentially regulated in the cerebrospinal fluid (CSF) of patients with MS. The awarded grant will allow him and a network of German centers to validate their initial findings of altered microRNA patterns in the CSF of up to 1000 patients with MS.

Dr. Kevin O’Connor, Assistant Professor of Neurology at Yale School of Medicine studies immunology and neurology. His laboratory is specifically interested in defining the mechanisms by which immune cells called B cells, and the antibodies they produce, influence tissue damage in autoimmunity. The grant will be used to support work in determining the specificity of autoantibodies and understanding how particular types of B cells initiate and sustain autoimmunity.

Dr. Joshua Bacon, Chair of the Department of Psychology at Stern College for Women at Yeshiva University in New York City, research scientist in the Department of Neurology at NYU School of Medicine, and member of the clinical and research team at NYU Langone’s Multiple Sclerosis Comprehensive Care Center, will use the grant to support his research developing tests to detect speedof-processing impairments in sub-clinical and early MS and developing a comprehensive cognitive rehabilitation program for patients with MS who also have cognitive impairments.

The GMSI was launched in October 2012 at the 28th ECTRIMS Congress with the aim of improving the understanding of MS for the ultimate benefit of those living with the disease. Researchers from across the globe were invited to submit proposals describing promising translational research projects. More than 100 proposals were received.

https://www.bionity.com/en/news/145269/merck-serono-makes-first-awards-for-multiple-sclerosis-innovation.html